Bullfrog AI (BFRG) Competitors $1.34 +0.03 (+1.89%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BFRG vs. KPTI, INMB, CELU, CUE, JATT, ATNM, BRNS, FGEN, PDSB, and AADIShould you be buying Bullfrog AI stock or one of its competitors? The main competitors of Bullfrog AI include Karyopharm Therapeutics (KPTI), INmune Bio (INMB), Celularity (CELU), Cue Biopharma (CUE), JATT Acquisition (JATT), Actinium Pharmaceuticals (ATNM), Barinthus Biotherapeutics (BRNS), FibroGen (FGEN), PDS Biotechnology (PDSB), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. Bullfrog AI vs. Its Competitors Karyopharm Therapeutics INmune Bio Celularity Cue Biopharma JATT Acquisition Actinium Pharmaceuticals Barinthus Biotherapeutics FibroGen PDS Biotechnology Aadi Bioscience Bullfrog AI (NASDAQ:BFRG) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Does the media prefer BFRG or KPTI? In the previous week, Karyopharm Therapeutics had 16 more articles in the media than Bullfrog AI. MarketBeat recorded 19 mentions for Karyopharm Therapeutics and 3 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.83 beat Karyopharm Therapeutics' score of 0.22 indicating that Bullfrog AI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bullfrog AI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger valuation and earnings, BFRG or KPTI? Bullfrog AI has higher earnings, but lower revenue than Karyopharm Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBullfrog AI$60K229.77-$6.99M-$0.76-1.77Karyopharm Therapeutics$145.24M0.36-$76.42M-$14.59-0.41 Do insiders and institutionals hold more shares of BFRG or KPTI? 1.0% of Bullfrog AI shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 25.2% of Bullfrog AI shares are held by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate BFRG or KPTI? Karyopharm Therapeutics has a consensus price target of $18.20, suggesting a potential upside of 201.32%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is BFRG or KPTI more profitable? Bullfrog AI has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity.Company Net Margins Return on Equity Return on Assets Bullfrog AIN/A -195.35% -162.37% Karyopharm Therapeutics -90.02%N/A -84.28% Which has more volatility & risk, BFRG or KPTI? Bullfrog AI has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. SummaryKaryopharm Therapeutics beats Bullfrog AI on 9 of the 16 factors compared between the two stocks. Get Bullfrog AI News Delivered to You Automatically Sign up to receive the latest news and ratings for BFRG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BFRG vs. The Competition Export to ExcelMetricBullfrog AIMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.79M$2.21B$6.05B$10.24BDividend YieldN/AN/A5.73%4.78%P/E Ratio-1.7737.4686.3326.55Price / Sales229.7711.23600.12186.81Price / CashN/A62.0425.7330.17Price / Book2.3612.8112.866.52Net Income-$6.99M-$63.46M$3.31B$276.31M7 Day Performance-10.33%-4.12%-0.74%-2.92%1 Month Performance1.36%3.50%8.31%4.14%1 Year Performance-50.19%38.28%79.14%30.13% Bullfrog AI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BFRGBullfrog AI0.56 of 5 stars$1.35+1.9%N/A-51.1%$13.79M$60K-1.774Gap UpKPTIKaryopharm Therapeutics3.9868 of 5 stars$6.50+2.4%$34.00+423.1%-57.4%$56.36M$145.24M-0.45380Analyst RevisionINMBINmune Bio2.6927 of 5 stars$2.08-1.7%$18.50+791.6%-63.8%$55.15M$10K-0.8410Positive NewsGap UpCELUCelularity2.0473 of 5 stars$2.05-4.9%$6.00+193.4%-18.3%$54.58M$54.22M-0.64220CUECue Biopharma2.5625 of 5 stars$0.70-2.7%N/A-35.3%$53.80M$9.29M-1.2560Positive NewsJATTJATT AcquisitionN/A$2.99+24.1%N/A+2.2%$51.58MN/A0.003Gap DownHigh Trading VolumeATNMActinium Pharmaceuticals1.8698 of 5 stars$1.61-0.9%$4.50+180.4%-17.2%$50.07MN/A-1.1530News CoverageBRNSBarinthus Biotherapeutics2.4222 of 5 stars$1.22-17.6%$3.00+145.9%+16.2%$49.68M$14.97M-0.71107Gap UpFGENFibroGen4.3346 of 5 stars$12.24-0.7%$43.00+251.5%+18.1%$49.49M$29.62M-32.24570PDSBPDS Biotechnology2.1375 of 5 stars$1.02+0.5%$10.00+885.2%-72.3%$47.74MN/A-1.1020AADIAadi BioscienceN/A$1.92-1.0%N/A-1.5%$47.42M$25.07M-0.8440 Related Companies and Tools Related Companies Karyopharm Therapeutics Competitors INmune Bio Competitors Celularity Competitors Cue Biopharma Competitors JATT Acquisition Competitors Actinium Pharmaceuticals Competitors Barinthus Biotherapeutics Competitors FibroGen Competitors PDS Biotechnology Competitors Aadi Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BFRG) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bullfrog AI Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bullfrog AI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
